Kathleen W Zhang1, Brian S Finkelman2, Gaurav Gulati3, Hari K Narayan4, Jenica Upshaw3, Vivek Narayan5, Ted Plappert6, Virginia Englefield6, Amanda M Smith6, Carina Zhang6, W Gregory Hundley7, Bonnie Ky8. 1. Division of Cardiology, Barnes-Jewish Hospital, St. Louis, Missouri. 2. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 3. Division of Cardiology, Tufts Medical Center, Boston, Massachusetts. 4. Department of Pediatrics, Division of Cardiology, Rady Children's Hospital San Diego, The University of California-San Diego, San Diego, California. 5. Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 6. Penn Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 7. Division of Cardiology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Penn Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Center for Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Electronic address: bonnie.ky@uphs.upenn.edu.
Abstract
OBJECTIVES: The objective of this study was to evaluate the changes in three-dimensional (3D) speckle-tracking echocardiography-derived measures of mechanics and their associations with systolic and diastolic dysfunction after anthracyclines. BACKGROUND: An improved understanding of the changes in 3D cardiac mechanics with anthracyclines may provide important mechanistic insight and identify new metrics to detect cardiac dysfunction. METHODS: A total of 142 women with breast cancer receiving doxorubicin (240 mg/m2) with or without trastuzumab underwent 3D speckle-tracking echocardiography at standardized intervals prior to, during, and annually after chemotherapy. Left ventricular ejection fraction (LVEF), global circumferential strain (GCS), global longitudinal strain (GLS), principal strain, twist, and torsion were quantified. Linear regression analyses defined the associations between clinical factors and 3D parameters. Linear regression models with cluster robust variance estimators determined the associations between 3D measures and 2-dimensional (2D) LVEF and Doppler-derived E/e' over time. RESULTS: There were significant abnormalities in 3D LVEF, GCS, GLS, and principal strain post-doxorubicin compared with control subjects (p < 0.001). The 3D parameters worsened post-anthracyclines, and only partially recovered to baseline over a median of 2.1 years (interquartile range: 1 to 4 years). Higher blood pressure and body mass index were associated with worse post-anthracycline 3D GCS and GLS, respectively. All 3D measures were associated with 2D LVEF at the same visit; only 3D LVEF, GCS, GLS, and principal strain were associated with 2D LVEF at subsequent visits (p < 0.05). In exploratory analyses, 3D LVEF and GCS were associated with subsequent systolic function independent of their corresponding 2D measures. The 3D LVEF, GCS, principal strain, and twist were significantly associated with concurrent, but not subsequent, E/e'. CONCLUSIONS: Anthracyclines result in early and persistent abnormalities in 3D mechanics. The 3D LVEF and strain measures are associated with concurrent and subsequent systolic dysfunction, and concurrent diastolic dysfunction. Future research is needed to define the mechanisms and clinical relevance of abnormal 3D mechanics.
OBJECTIVES: The objective of this study was to evaluate the changes in three-dimensional (3D) speckle-tracking echocardiography-derived measures of mechanics and their associations with systolic and diastolic dysfunction after anthracyclines. BACKGROUND: An improved understanding of the changes in 3D cardiac mechanics with anthracyclines may provide important mechanistic insight and identify new metrics to detect cardiac dysfunction. METHODS: A total of 142 women with breast cancer receiving doxorubicin (240 mg/m2) with or without trastuzumab underwent 3D speckle-tracking echocardiography at standardized intervals prior to, during, and annually after chemotherapy. Left ventricular ejection fraction (LVEF), global circumferential strain (GCS), global longitudinal strain (GLS), principal strain, twist, and torsion were quantified. Linear regression analyses defined the associations between clinical factors and 3D parameters. Linear regression models with cluster robust variance estimators determined the associations between 3D measures and 2-dimensional (2D) LVEF and Doppler-derived E/e' over time. RESULTS: There were significant abnormalities in 3D LVEF, GCS, GLS, and principal strain post-doxorubicin compared with control subjects (p < 0.001). The 3D parameters worsened post-anthracyclines, and only partially recovered to baseline over a median of 2.1 years (interquartile range: 1 to 4 years). Higher blood pressure and body mass index were associated with worse post-anthracycline 3D GCS and GLS, respectively. All 3D measures were associated with 2D LVEF at the same visit; only 3D LVEF, GCS, GLS, and principal strain were associated with 2D LVEF at subsequent visits (p < 0.05). In exploratory analyses, 3D LVEF and GCS were associated with subsequent systolic function independent of their corresponding 2D measures. The 3D LVEF, GCS, principal strain, and twist were significantly associated with concurrent, but not subsequent, E/e'. CONCLUSIONS:Anthracyclines result in early and persistent abnormalities in 3D mechanics. The 3D LVEF and strain measures are associated with concurrent and subsequent systolic dysfunction, and concurrent diastolic dysfunction. Future research is needed to define the mechanisms and clinical relevance of abnormal 3D mechanics.
Authors: Hans-Joachim Nesser; Victor Mor-Avi; Willem Gorissen; Lynn Weinert; Regina Steringer-Mascherbauer; Johannes Niel; Lissa Sugeng; Roberto M Lang Journal: Eur Heart J Date: 2009-05-29 Impact factor: 29.983
Authors: A Evangelista; S Gabriele; P Nardinocchi; P Piras; P E Puddu; L Teresi; C Torromeo; V Varano Journal: J Biomech Date: 2014-12-16 Impact factor: 2.712
Authors: Paaladinesh Thavendiranathan; Andrew D Grant; Tomoko Negishi; Juan Carlos Plana; Zoran B Popović; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2012-11-28 Impact factor: 24.094
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Circ Cardiovasc Imaging Date: 2012-06-28 Impact factor: 7.792
Authors: Hong-kui Yu; Wei Yu; Daniel K L Cheuk; Sophia J Wong; Godfrey C F Chan; Yiu-fai Cheung Journal: J Am Soc Echocardiogr Date: 2013-05-31 Impact factor: 5.251
Authors: April C Childs; Sharon L Phaneuf; Amie J Dirks; Tracey Phillips; Christiaan Leeuwenburgh Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: Andreas Seraphim; Mark Westwood; Anish N Bhuva; Tom Crake; James C Moon; Leon J Menezes; Guy Lloyd; Arjun K Ghosh; Sarah Slater; Heather Oakervee; Charlotte H Manisty Journal: Curr Treat Options Oncol Date: 2019-08-08
Authors: Markus S Anker; Sara Hadzibegovic; Alessia Lena; Yury Belenkov; Jutta Bergler-Klein; Rudolf A de Boer; Dimitrios Farmakis; Stephan von Haehling; Zaza Iakobishvili; Christoph Maack; Radek Pudil; Hadi Skouri; Alain Cohen-Solal; Carlo G Tocchetti; Andrew J S Coats; Petar M Seferović; Alexander R Lyon Journal: ESC Heart Fail Date: 2019-12-28